Shi Y, Li Y, Chen W, Zhang M, Qian D, Li T, Dai Y, Li G. Cost-effectiveness analysis of Sintilimab vs. Docetaxel as the second-line therapy of squamous non-small cell lung cancer in China. Health Decision [Internet]. 2024 Jul. 12 [cited 2025 May 2];2(S1). Available from: https://www.hksmp.com/journals/hd/article/view/653